anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Electroconvulsive therapy (ECT) is the most potent psychiatric treatment, with an effect size of 1.5 for severe and refractory unipolar and bipolar depression. ECT convincingly outperforms pharmacotherapy such as tricyclic antidepressants and monoamine oxidase inhibitors and any form of psychotherapy. Despite its outstanding performance in reducing depressive symptoms up to the point of full remission, it is used only marginally. One reason for its infrequent use may be that the response to ECT is largely unpredictable, while cognitive side-effects occur frequently.

In a previous study, the researchers found that multiple cognitive tests showed a significant decline immediately post-ECT, which resolved within 6 months after the last ECT session without further treatment. Even though cognitive side-effects are mostly short-lasting, both patients and doctors see this as a great drawback of ECT. If these disturbing side-effects could be prevented, more patients and psychiatrists would choose ECT as a treatment option. This would lead to a more effective treatment and hence shorter duration of chronic severe depression and improvement in quality of life, while costs for health care and loss of productivity would decrease. A potential way of ameliorating side effects, could be to add a cholinesterase inhibitor to ECT treatment. Rodent studies show that the loss of cholinergic fibers specifically correlated to the cognitive side effects of rodents after electroconvulsive stimulation (ECS). The researchers selected rivastigmine (a cholinesterase inhibitor) as a potential candidate in counteracting cognitive side effects induced by cholinergic fiber loss due to ECT. Rivastigmine patches are very well tolerated and widely used for Alzheimer's and Parkinson's dementia.

Tailoring treatment to patients that are likely to respond while cognitive side-effects are unlikely to occur, would be another important improvement for depressed patients. Currently, ECT outcome is unpredictable. Factors that favor response include older age, psychotic depression, shorter duration of the depressive episode, and smaller volumes of the dentate gyrus (a part of the hippocampus). However, these predictors do not provide enough accuracy to make individual response profiles. Accurately classifying specifically non-responders will prevent application of ineffective treatment with potential iatrogenic damage, while more accurately predicted response will increase the applicability of ECT as treatment option. A potentially powerful way that is easy to implement in the clinic is prediction of ECT response using resting state EEG characteristics in addition to clinical information.
PURPOSE:To facilitate a priming operation, to decrease the damages that blood cells receive and to lessen the deterioration in the blood cell sticking behabior of a blood cell sepn. filter with lapse of time by forming the filter material of the filter to a wet state above a satd. moisture content. CONSTITUTION:The blood cell filter is formed by setting a non-woven filter layer 4 made of polyethylene terephthalate into a column body 1 combined with two sheets of square-shaped frame bodies 2, 2' and press-welding the peripheral part thereof. Projections 3, 3' are provided on the inside of a column body 1 to partially support the central part of the filter layer 4. Blood to be treated enters the filter through an inlet 5 and the separated blood emerges from the filter through an outlet 6. The filter layer 4 is maintained in the wet state above the satd. moisture content by water or water soluble materials which are harmless to the living body, for example, aq. solns. of sodium chloride and sodium carbonate. Said layer is sterilized by methods of sterilization such as heating, filtration, irradiation, gas and liquid chemical, more preferably heating by high-pressure vapor or irradiation by radiations.
FIELD: chemical technology. SUBSTANCE: method involves contact of reaction mixture containing organic solvent, aldehyde and hydrocyanic acid by passing through porous diaphragm. The latter has resin-like polymeric binding agent containing finely milled filling agent particles dispersed in binding agent where enzyme S-hydroxynitrilase is bound chemically by immobilization by cobalent or cross-linking enzyme bonds with binding agent. Diaphragm is activated chemically with polyethyleneimine and glutaric dialdehyde. Method is used in agriculture, an intermediate product for insecticides production. EFFECT: improved method of producing. 10 cl, 4 tbl
The present invention provides two novel human cathepsin proteins (HCPs) and polynucleotides encoding HCPs. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HCPs. The invention also provides for the production and use of antibodies to HCPs in pharmaceutical compositions for the treatment of disease processes that include cancers, inflammation, metastasis and peptide and proenzyme processing. In addition, the invention provides for the production and use of inhibitors of HSPs in pharmaceutical compositions for the treatment of diseases. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HCPs. The invention also provides for the use of antisense molecules in pharmaceutical compositions as a therapeutics in cancers, inflammation, metastasis and peptide and proenzyme processing.
The invention discloses a processing method of a fresh solanum nigrum fruit. The processing method comprises the following steps of 1, picking immature solanum nigrum fruits having dark green and bluish yellow colors on June to August, wherein before picking, a small amount of the solanum nigrum fruits is picked and then is added with water of which the amount is the same as that of the picked solanum nigrum fruits, the mixture is subjected to homogenization fragmentation, the fragmented mixture is filtered and the filtrate has colors from dark green to bluish yellow colors but reddish brown and rose colors, and 2, removing impurities and fruit stems of the picked solanum nigrum fruits, selecting the solanum nigrum fruits which have undamaged peel, do not leak juice, have plump shapes and have detected fruit hardness of 7-2Kg.cm<-1>, cleaning the solanum nigrum fruits by water, and carrying out draining to obtain solanum nigrum fruit finished products. The invention also discloses solanum nigrum fruit extract particles prepared from the solanum nigrum fruits treated by the processing method and a use thereof. The raw materials obtained by the processing method have high effective ingredient content. The products obtained the processing method can be stored and transported easily. After water decoction or water dissolution, the effective ingredient content of the product is obviously higher than those of a fresh-fruit water decoction and a dry-fruit water decoction. After water decoction or water dissolution, the product is used and has effects of resisting tumors.
This invention provides for the active site mapping of enzymes which catalyse covalent modification including, but not limited to phosphorylation, acylation, dephosphorylation in which a fixed residue (known as the catalytic residue) such as a tyrosine, serine, threonine, histidine, aspartic acid residue or any other residue containing an appropriate side chain is modified.  Mapping of protein kinases is exemplified. The method of the invention has an additional level of complexity over and above that of the self-deconvoluting libraries described in WO97/42216. This involves making a library of smaller libraries (referred to as subsets) where a fixed residue is moved stepwise through the sequence of amino acids or other groups (such as peptidomimetics).  Using 5 subsets of libraries of peptides of 5 amino acids allows the mapping of a sequence of 9 amino acids. In general one could carry out the invention using n subsets of n-mer peptides so as to provide mapping data for the residues from -(n-1) to +(n-1) either side of the active site. Thus in general the length of the mapped sequence would be (2n)-1. In this invention there is no need to separate modified from unmodified sequences because of the self deconvoluting nature of the library. The assay screen produces a series of hits, the patterns of which reveal the unique sequences in each well. This enables a pattern of substrate preferences to be determined for any enzyme.  The unique sequences obtained using this invention can be used to provide substrates for high throughput assays and provide detailed information about the active site to aid rational drug design. This invention can also be used as an inhibitor library to screen against known modifying enzymes where a known substrate exists and can be set up in an assay format.
Introduction. Disruptions in gut microbiota, known as dysbiosis, have been increasingly linked to pathogenic infections, with Salmonella Typhimurium being a notable contributor to these disturbances.Hypothesis. We hypothesize that the S. Typhimurium 14028 WT strain induces significant dysbiosis in the rat gut microbiota and that the dam and seqA genes play crucial roles in this process.Aim. In this study, it was aimed at investigating the dysbiotic activity of the S. Typhimurium 14028 WT strain on the rat gut microbiota and the roles of dam and seqA genes on this activity.Method. Changes in the rat gut microbiota were determined by examining the anal swap samples taken from the experimental groups of these animals using 16S rRNA high-throughput sequencing technology.Results. In the experimental groups, the dominant phyla were determined to be Firmicutes and Bacteroidetes (P<0.05). However, while the rate of Bacteroidetes was significantly reduced in those treated with the WT and seqA mutants, no significant difference was observed in the dam mutant compared to the control group (P<0.05). In all experimental animals, the dominant species was determined to be Prevotella copri, regardless of the experiment time and application. The analysis results of the samples taken on the third day from the rat groups infected with the S. Typhimurium 14028 WT strain (W2) presented the most striking data of this study.Conclusion. Through distance analysis, we demonstrated that a successful Salmonella infection completely changes the composition of the microbiota, dramatically reduces species diversity and richness in the microbiota and encourages the growth of opportunistic pathogens.
The subjects will receive in Period 1 either the low-dose or high-dose first, and in Period 2 they will receive the alternate dose. There is a washout period between periods.
Risperidone and olanzapine are atypical neuroleptics marketed for the treatment of psychotic disorders in adults. These medicines are called atypical neuroleptics because of their unique pharmacological profile, which include both D2 and 5HT2 antagonistic effects. The combined dopaminergic and serotonergic activity seems to be associated not only with antipsychotic effects, but also with mood stabilizing, mood elevating and tardive dyskinesia. The anti-climactic effects of this class of drugs led to the recent FDA approval of olanzapine as monotherapy for adult bipolar disorder.

The study will consist of 8 week, open-label treatment period with random assignment to two determined treatment arms, risperidone or olanzapine. We plan to enroll 5 subjects for each arm. During the 8 weeks of treatment, patients will be seen at weekly intervals and receive study medication. At each week, measures of safety and efficacy will be obtained. Two teams of clinicians will see the patient at each visit. Team 1 will be the treating team, adjusting medication dosages and determining the safety of continuation in the study for the patient. Team 2 will be blind to the randomization status of the patient and will assess clinical improvement using the efficacy measures. For patients who have completed the 8-week acute phase without adverse event and have not responded to the medication they were assigned to will be allowed to then take part in additional 8-week trial with the other medication. At the end of the 8 weeks, patients who responded to their assigned treatment will be eligible to be enrolled and invited to participate in a separate10 month continuation study.
A pharmaceutical composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s) and release controlling agent(s). Pharmaceutical composition of rifaximin comprising: at least two entities wherein one entity is an immediate release or fast release and the other is controlled release. The pharmaceutical composition in the form of multilayer tablet comprising, at least one layer comprising, therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s); said layer providing controlled release rifaximin; and at least one layer which provides increased residence time of the dosage form in the gastrointestinal tract. The pharmaceutical formulation comprising rifaximin having an in vitro dissolution profile, wherein about 70% of rifaximin is released in about 24 hours. The composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) thereof, one or more release controlling agent(s) and pharmaceutically acceptable excipient(s) causing pathogenic eradication. 7853190 1 (GHMatters) P83017.AU.2
Randomized phase 2, multicenter, clinical trial to assess the efficacy of PARP inhibitor plus Temozolomide (TMZ) in biomarker selected relapsed SCLC patients. The investigators will test for sensitivity of two biomarkers in the blood SLFN11 and MGMT. Biomarker-positive (sensitive) patients are randomized 2:1 to either experimental Arm 2 (PARP inhibitor 200mg + 40mg TMZ oral daily for 21 days or 3.2mg/m2 Lurbinectedin IV infusion over one-hour every 21 days.). This requires 101 sensitive patients (67 on combination drug and 34 on Lurbinectedin). Biomarker-negative (resistant) patients will be enrolled on the control Arm 1 standard of care 3.2mg/m2 Lurbinectedin IV infusion over one-hour every 21 days. This requires 51 resistant patients on the control arm. The investigators will determine if biomarker (positive) sensitive patients will benefit from the oral combination PARP inhibitor + TMZ.
Participants will be treated with placebo PBMT in different time-points before the eccentric exercise protocol (5 minutes, 3 hours, 6 hours or 24 hours). Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
FIELD: medicine. SUBSTANCE: method involves administering anti- inflammatory therapy, vitamins combined with a basic therapy. The main medicine to be used is oxydevit, which is administered to begin with a minimum therapeutic dose of 0.25 mcg per day with daily dose increment being 0.2-0.25 mcg to reach the dose of 0.5-1.5 mcg. Oxydevit is to be ingested 40-60 min before going to bed in the night time between 9 and 11 p.m. and additionally between 1 and 3 p.m. during the dinner meal, calcium and phosphorus preparations are administered to be taken once in the amount of a daily therapeutic dose. EFFECT: reduced probability of relapsing disease, longer duration of remittance period. 4 dwg
PURPOSE: A stratiform perforated biomatrix is provided to be used for a cosmetic product and treatment. CONSTITUTION: A stratiform perforated biomatrix is formed of units(2) which are regularly arranged. The biomatrixes are connected each other by continuous holes(3). The units are formed in a triangle, rectangle, beehive, or circle. The biomatrix is formed of hydrophilic polymers a carrier material containing an active ingredient or additives. The active ingredient is hemostatic and/or wound healing agent.
Three concentrations of E6201 topical gel (0.005%, 0.01%, and 0.05%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. Cohort 2 participants were not dosed until all participants in Cohort 1 completed treatment and safety data were collected and evaluated.
Adrenocorticotropin (ACTH) secretion is normally exquisitely regulated through endogenous stimulation by corticotrophin-releasing hormone (CRH) and negative feedback inhibition by cortisol, resulting in a circadian rhythm of cortisol. Recent evidence suggests that older men, and younger men who are endurance-trained athletes, both have reduced sensitivity to negative feedback, and perhaps increased basal levels of cortisol and ACTH. To investigate these possibilities, we propose to examine multiple aspects of the hypothalamic-pituitary-adrenal axis in younger endurance trained and sedentary men, and in older sedentary men.

Subjects will collect saliva during two evenings before additional testing, and will on the same evening collect urine for twelve hours, both for cortisol measurements. Blood samples will be collected to evaluate the response to dexamethasone. We also will assess ACTH and cortisol responses to medications that reduce negative inhibition of ACTH. This testing will occur in the evening and will include administration of the glucocorticoid antagonist mifepristone, the mineralocorticoid antagonist spironolactone, and/or a look-alike tablet, on four occasions.
FIELD: biotechnology, microbiology. SUBSTANCE: polysaccharide of Neisseria MENINGITIDES group B modified by substitution of N-acetyl groups of sialic acids residue with C 4 -C 8 --acyl groups exhibits enhanced immune response. Induction of antibodies that show cross-over interaction with nonmodified meningococcal capsule polysaccharide group B and other tissue cells of simple epitope is decreased to minimal values. Conjugation of modified polysaccharide with physiologically acceptable protein, for example, tetanus anatoxin, induces production of specific protective antibodies at nonsignificant levels of GVMP - cross-over reacting antibodies. This provides protection against infections caused by meningococcus of group B. EFFECT: improved method of induction. 18 cl, 5 tbl, 1 ex
Background: Magnesium (Mg) is an essential element and participates in many metabolic pathways. Many studies have found a certain negative correlation between magnesium and blood glucose parameters, but the dose-response relationship between them is still a relatively narrow research field. We aim to explore the dose-response relationship between plasma and dietary Mg and type 2 diabetes (T2DM) among childbearing women in a nationally representative sample. And we will also initially explore the threshold of dietary and plasma magnesium in the prevention of T2DM and their consistency. Methods: A total of 2912 18-44 year-old childbearing women were recruited from the China Adult Chronic Disease and Nutrition Surveillance (2015). Multivariate logistic regression was used to explore the dose-response relationship between plasma and dietary Mg and glucose parameters. The threshold effect between Mg and T2DM was explored by a restricted cubic spline regression. Results: It was found that when plasma Mg was increased by 0.041 mmol/L, the risk of T2DM, impaired fasting glucose (IFG), and HbA1c-hyperglycemia was reduced by 18%, 19%, and 18%, respectively. The possible threshold value for plasma Mg to prevent the risk of T2DM was 0.87 mmol/L. Through the quality control of the sample dietary survey data, 2469 cases were finally included for dietary analysis. And the possible threshold value for dietary Mg to prevent the risk of T2DM was 408 mg/d. Taking the recommended dietary Mg intake of 330 mg/d as the reference group, when the Mg intake reached 408 mg/d, the risk of T2DM was significantly reduced. And the average plasma Mg level of the people whose dietary intake reached 408 mg/d was 0.87 mmol/L. Conclusions: These results indicate that dietary Mg and plasma Mg have good consistency on the threshold effect of glucose parameters in women of childbearing age.
1289693 Ampicillin preparations BRISTOLMYERS CO 3 Dec 1969 [4 Dec 1968] 59080/69 Heading A5B An ampicillin preparation which is readily suspendable in aqueous media to provide stable suspensions, e.g. for injection, is made by coating particles of ampicillin of size below 200 mesh U.S.S.S. with lecithin and polyvinylpyrrolidone. They may be made by conventional methods, e.g. by contacting the ampicillin particles with a solution of the colloid and surfactant in a volatile solvent which is evaporated from the mixture. Additional conventional ingrediets, e.g. a preservative and a source of sodium ions, e.g. NaCl and/or sodium citrate, may also be present.
[GB1289693A]
A study was undertaken to determine how well contacting fracture fragments of composite bone replicated the behavior of fracture fragments in real bone. Ten composite and ten real humeral diaphyses were transected and reconstructed with limited-contact dynamic-compression plates. Two screws were placed on each side of the transection site and a calibrated electronic sensor sheet was placed between the imitated fracture fragments. After insertion of the distal screws, pressure measurements were made during insertion of the first proximal screw in compression mode, during insertion of the second screw in compression mode after loosening the first screw, and finally after retightening the first screw. The process was repeated after bending the plate. The contact area, the net compression force and the average compressive stress were computed and statistically compared. The composite bone and cadaveric bone differed in contact area and compressive stress but not in net compressive force. Plate bending did not produce a significant difference between composite and cadaveric bone. The results indicate that composite bone does not reproduce all the local fracture fragment conditions so that hardware testing in composite bone should proceed carefully. A gap between fracture fragments as is often used in comminuted fracture tests may remain as the most appropriate situation for fracture hardware testing.
INTRODUCTION: To effectively support patients through their weight loss journey, it is vital that healthcare professionals (HCPs) understand the health literacy skills of their patients and communicate in a way that meets these needs. This is the first study looking at the accuracy of HCPs' estimations of their patients' health literacy and numeracy attending a metabolic bariatric surgery (MBS) clinic.
METHOD: A cross-sectional study was completed at a tertiary-level MBS clinic in London. Patients completed a demographic questionnaire and a validated measure of health literacy and numeracy, the Medical Term Recognition Test (METER) and General Health Numeracy Test-Short Form (GHNT-6), respectively. HCPs provided estimations of their patient's health literacy and numeracy based on each questionnaire's scoring categories.
RESULTS: Data was collected for 31 patients. A 80.6% of patients had functional health literacy based on METER. HCPs estimated patients' health literacy correctly 61.1% of the time; inter-rater agreement was poor (ICC = 0.14; 95% CI =  - 0.19, 0.443; p = 0.202). A total of 22.6% of patients scored 0 out of 6 on GHNT-6. HCPs estimated health numeracy correctly 13.9% of the time and were more likely to overestimate than underestimate health numeracy. Inter-rater agreement for health numeracy was poor (ICC =  - 0.2; 95% CI =  - 0.49, 0.14; p = 0.878).
CONCLUSION: There is poor agreement between HCPs' perception of their patients' health literacy and numeracy and their assessed ability. HCPs' understanding of their patient's health literacy and numeracy skills is vital in ensuring HCPs can support patients through the challenging bariatric surgical pathway, consenting process and post-operative course.